7T MRI for Cushing Disease: A Single-Institution Experience and Literature Review

References

1. 1.↵
   1. Castle-Kirszbaum M,
   2. Amukotuwa S,
   3. Fuller P, et al

   . MRI for Cushing disease: a systematic review. AJNR Am J Neuroradiol 2023;44:311–16 doi:10.3174/ajnr.A7789 pmid:36759141

   Abstract/FREE Full Text
2. 2.↵
   1. Bashari WA,
   2. Gillett D,
   3. MacFarlane J, et al

   . Modern imaging in Cushing’s disease. Pituitary 2022;25:709–12 doi:10.1007/s11102-022-01236-w pmid:35666391

   CrossRefPubMed
3. 3.↵
   1. Lonser RR,
   2. Nieman L,
   3. Oldfield EH

   . Cushing’s disease: pathobiology, diagnosis, and management. J Neurosurg 2017;126:404–17 doi:10.3171/2016.1.JNS152119 pmid:27104844

   CrossRefPubMed
4. 4.↵
   1. Ntali G,
   2. Asimakopoulou A,
   3. Siamatras T, et al

   . Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013;169:715–23 doi:10.1530/EJE-13-0569 pmid:23996696

   Abstract/FREE Full Text
5. 5.↵
   1. Lonser RR,
   2. Wind JJ,
   3. Nieman LK, et al

   . Outcome of surgical treatment of 200 children with Cushing’s disease. J Clin Endocrinol Metab 2013;98:892–901 doi:10.1210/jc.2012-3604 pmid:23372173

   CrossRefPubMed
6. 6.↵
   1. Newell-Price J,
   2. Bertagna X,
   3. Grossman AB, et al

   . Cushing’s syndrome. Lancet 2006;367:1605–17 doi:10.1016/S0140-6736(06)68699-6 pmid:16698415

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Pinker K,
   2. Ba-Ssalamah A,
   3. Wolfsberger S, et al

   . The value of high-field MRI (3T) in the assessment of sellar lesions. Eur J Radiol 2005;54:327–34 doi:10.1016/j.ejrad.2004.08.006 pmid:15899332

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Stobo DB,
   2. Lindsay RS,
   3. Connell JM, et al

   . Initial experience of 3 Tesla versus conventional field strength magnetic resonance imaging of small functioning pituitary tumours. Clin Endocrinol (Oxf) 2011;75:673–77 doi:10.1111/j.1365-2265.2011.04098.x pmid:21609346

   CrossRefPubMed
9. 9.↵
   1. Kim LJ,
   2. Lekovic GP,
   3. White WL, et al

   . Preliminary experience with 3-Tesla MRI and Cushing’s disease. Skull Base 2007;17:273–77 doi:10.1055/s-2007-985196 pmid:18174929

   CrossRefPubMed
10. 10.↵
    1. Trattnig S,
    2. Springer E,
    3. Bogner W, et al

    . Key clinical benefits of neuroimaging at 7T. Neuroimage 2018;168:477–89 doi:10.1016/j.neuroimage.2016.11.031 pmid:27851995

    CrossRefPubMed
11. 11.↵
    1. Burkett BJ,
    2. Fagan AJ,
    3. Felmlee JP, et al

    . Clinical 7-T MRI for neuroradiology: strengths, weaknesses, and ongoing challenges. Neuroradiology 2021;63:167–77 doi:10.1007/s00234-020-02629-z pmid:33388947

    CrossRefPubMed
12. 12.↵
    1. de Rotte AAJ,
    2. van der Kolk AG,
    3. Rutgers D, et al

    . Feasibility of high-resolution pituitary MRI at 7.0 Tesla. Eur Radiol 2014;24:2005–11 doi:10.1007/s00330-014-3230-x pmid:24871334

    CrossRefPubMed
13. 13.↵
    1. de Rotte AA,
    2. Groenewegen A,
    3. Rutgers DR, et al

    . High-resolution pituitary gland MRI at 7.0 Tesla: a clinical evaluation in Cushing’s disease. Eur Radiol 2016;26:271–77 doi:10.1007/s00330-015-3809-x pmid:25991481

    CrossRefPubMed
14. 14.↵
    1. Law M,
    2. Wang R,
    3. Liu CJ, et al

    . Value of pituitary gland MRI at 7 T in Cushing’s disease and relationship to inferior petrosal sinus sampling: case report. J Neurosurg 2018 Mar 1. [Epub ahead of print] doi:10.3171/2017.9.JNS171969 pmid:29570013

    CrossRefPubMed
15. 15.↵
    1. Patel V,
    2. Liu CJ,
    3. Shiroishi MS, et al

    . Ultra-high field magnetic resonance imaging for localization of corticotropin-secreting pituitary adenomas. Neuroradiology 2020;62:1051–54 doi:10.1007/s00234-020-02431-x pmid:32306052

    CrossRefPubMed
16. 16.↵
    1. Eisenhut F,
    2. Schlaffer SM,
    3. Hock S, et al

    . Ultra-high-field 7 T magnetic resonance imaging including dynamic and static contrast-enhanced T1-weighted imaging improves detection of secreting pituitary microadenomas. Invest Radiol 2022;57:567–74 doi:10.1097/RLI.0000000000000872 pmid:35925660

    CrossRefPubMed
17. 17.↵
    1. Feng JJ,
    2. Cheok SK,
    3. Chartrain AG, et al

    . Endoscopic endonasal approach for MRI negative Cushing’s microadenoma. Neurosurg Focus Video 2023;9:V5 doi:10.3171/2023.4.FOCVID2324 pmid:37416812

    CrossRefPubMed
18. 18.↵
    1. Eisenhut F,
    2. Schmidt MA,
    3. Buchfelder M, et al

    . Improved detection of cavernous sinus invasion of pituitary macroadenomas with ultra-high-field 7 T MRI. Life (Basel) 2022;13:49 doi:10.3390/life13010049 pmid:36675998

    CrossRefPubMed
19. 19.↵
    1. Bonneville JF,
    2. Potorac I,
    3. Petrossians P, et al

    . Pituitary MRI in Cushing’s disease: an update. J Neuroendocrinol 2022;34:e13123 doi:10.1111/jne.13123 pmid:35352410

    CrossRefPubMed
20. 20.↵
    1. Tabarin A,
    2. Laurent F,
    3. Catargi B, et al

    . Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing’s disease. Clin Endocrinol (Oxf) 1998;49:293–300 doi:10.1046/j.1365-2265.1998.00541.x pmid:9861318

    CrossRefPubMed
21. 21.↵
    1. Kucharczyk W,
    2. Bishop JE,
    3. Plewes DB, et al

    . Detection of pituitary microadenomas: comparison of dynamic keyhole fast spin-echo, unenhanced, and conventional contrast-enhanced MR imaging. AJR Am J Roentgenol 1994;163:671–79 doi:10.2214/ajr.163.3.8079866 pmid:8079866

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Danieli L,
    2. Riccitelli GC,
    3. Distefano D, et al

    . Brain tumor-enhancement visualization and morphometric assessment: a comparison of MPRAGE, SPACE, and VIBE MRI techniques. AJNR Am J Neuroradiol 2019;40:1140–48 doi:10.3174/ajnr.A6096 pmid:31221635

    Abstract/FREE Full Text
23. 23.↵
    1. Guo R,
    2. Wu Y,
    3. Guo G, et al

    . Application of contrast-enhanced 3-dimensional T2-weighted volume isotropic turbo spin echo acquisition sequence in the diagnosis of prolactin-secreting pituitary microadenomas. J Comput Assist Tomogr 2022;46:116–23 doi:10.1097/RCT.0000000000001237 pmid:35099143

    CrossRefPubMed
24. 24.↵
    1. Lang M,
    2. Habboub G,
    3. Moon D, et al

    . Comparison of constructive interference in steady-state and T1-weighted MRI sequence at detecting pituitary adenomas in Cushing’s disease patients. J Neurol Surg B Skull Base 2018;79:593–98 doi:10.1055/s-0038-1642032 pmid:30456030

    CrossRefPubMed
25. 25.↵
    1. Wang J,
    2. Wu Y,
    3. Yao Z, et al

    . Assessment of pituitary micro-lesions using 3D sampling perfection with application-optimized contrasts using different flip-angle evolutions. Neuroradiology 2014;56:1047–53 doi:10.1007/s00234-014-1432-1 pmid:25249174

    CrossRefPubMed
26. 26.↵
    1. Grober Y,
    2. Grober H,
    3. Wintermark M, et al

    . Comparison of MRI techniques for detecting microadenomas in Cushing’s disease. J Neurosurg 2018;128:1051–57 doi:10.3171/2017.3.JNS163122 pmid:28452619

    CrossRefPubMed
27. 27.↵
    1. Chatain GP,
    2. Patronas N,
    3. Smirniotopoulos JG, et al

    . Potential utility of FLAIR in MRI-negative Cushing’s disease. J Neurosurg 2018;129:620–28 doi:10.3171/2017.4.JNS17234 pmid:29027863

    CrossRefPubMed
28. 28.↵
    1. Fukuoka H,
    2. Hirai T,
    3. Okuda T, et al

    . Comparison of the added value of contrast-enhanced 3D fluid-attenuated inversion recovery and magnetization-prepared rapid acquisition of gradient echo sequences in relation to conventional postcontrast T1-weighted images for the evaluation of leptomeningeal diseases at 3T. AJNR Am J Neuroradiol 2010;31:868–73 doi:10.3174/ajnr.A1937 pmid:20037130

    Abstract/FREE Full Text
29. 29.↵
    1. Osawa I,
    2. Nagawa K,
    3. Hara Y, et al

    . Utility of contrast-enhanced 3D STIR FLAIR imaging for evaluating pituitary adenomas at 3 Tesla. Eur J Radiol Open 2023;11:100500 doi:10.1016/j.ejro.2023.100500 pmid:37408663

    CrossRefPubMed
30. 30.↵
    1. Bartynski WS,
    2. Boardman JF,
    3. Grahovac SZ

    . The effect of MR contrast medium dose on pituitary gland enhancement, microlesion enhancement and pituitary gland-to-lesion contrast conspicuity. Neuroradiology 2006;48:449–59doi:10.1007/s00234-006-0085-0 pmid:16699802

    CrossRefPubMed
31. 31.↵
    1. Portocarrero-Ortiz L,
    2. Bonifacio-Delgadillo D,
    3. Sotomayor-González A, et al

    . A modified protocol using half-dose gadolinium in dynamic 3-Tesla magnetic resonance imaging for detection of ACTH-secreting pituitary tumors. Pituitary 2010;13:230–35 doi:10.1007/s11102-010-0222-y pmid:20182808

    CrossRefPubMed
32. 32.↵
    1. Noebauer-Huhmann IM,
    2. Szomolanyi P,
    3. Kronnerwetter C, et al

    . Brain tumours at 7T MRI compared to 3T-contrast effect after half and full standard contrast agent dose: initial results. Eur Radiol 2015;25:106–12 doi:10.1007/s00330-014-3351-2 pmid:25194707

    CrossRefPubMed
33. 33.
    1. Liu Z,
    2. Zhang X,
    3. Wang Z, et al

    . High positive predictive value of the combined pituitary dynamic enhanced MRI and high-dose dexamethasone suppression tests in the diagnosis of Cushing’s disease bypassing bilateral inferior petrosal sinus sampling. Sci Rep 2020;10:14694 doi:10.1038/s41598-020-71628-0 pmid:32895443

    CrossRefPubMed